JPRN-jRCT2080221312未知2 期
Phase II-III Clinical Study of CSG452(RG7201) in Patients with Type 2 Diabetes. -Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Comparative Study in Monotherapy
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Has been diagnosed with type 2 diabetes
- •-Has been receiving treatment with only idet and exercise therapy
- •-HbA1c (Japanese Diabetes Society [JDS] value) >=7.0% and <10.0%
- •-Body mass index (BMI) >=18.5 kg/m2 and <45.0 kg/m2
排除标准
- •Had the following history and/or complications within 24 weeks of tests for screening test
- •-Acute diabetic complications such as diabetic ketoacidosis or hyperglycemic hyperosmolar coma
- •-Acute coronary disease (acute myocardial infarction, unstable angina, etc.) or stroke
- •-Recurrent genitourinary tract infection, defined as two or more episodes of complicated or uncomplicated cystitis or pyelonephritis
- •-Impaired hepatic function
- •-Impaired renal function
研究者
相似试验
未知
3 期
Phase III Long-Term Combination Therapy of CSG452(RG7201) in Patients with Type 2 DiabetesType 2 diabetesJPRN-jRCT2080221315Chugai Pharmaceutical Co., Ltd.565
未知
3 期
Phase III Long-Term Monotherapy of CSG452(RG7201) in Patients with Type 2 DiabetesType 2 diabetesJPRN-jRCT2080221314Chugai Pharmaceutical Co., Ltd.192
未知
3 期
A phase II/III clinical study of R442 (Pegylated Interferon alfa-2a) for patients with chronic hepatitis B.chronic hepatitis BJPRN-jRCT2080220384Chugai Pharmaceutical Co., Ltd.
已完成
2 期
A phase II/III clinical study of R442(Pegylated Interferon alfa-2a) for patients with chronic hepatitis B.chronic hepatitis BJPRN-UMIN000000692CHUGAI PHARMACEUTICAL CO.LTD.260
进行中（未招募）
1 期
A phase II study of CP-751,871 in patients with recurrent and/or metastatic squamous head and neck carcinoma - IGF-1R protocolEUCTR2008-004707-59-FRCliniques Universitaires Saint Luc-Centre du Cancer